Results from the phase 2 study PATHWAY trial with tezepelumab went under post hoc analysis which indicated that annual asthma exacerbation rates were reduced irrespective of blood eosinophils counts, baseline body mass index (BMI) or participants IgE levels (Th2-low asthma patients) (168), suggesting that tezepelumab has broad efficacy across different phenotypes of asthma (157, 159, 160). The gene discussed is IGHE; the disease is asthma.